INT207551

From wiki-pain
Revision as of 17:08, 20 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.22
First Reported 2007
Last Reported 2009
Negated 1
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 1.18
Pain Relevance 0.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IGF1, GH1) extracellular region (IGF1, GH1) signal transduction (IGF1)
Anatomy Link Frequency
Thyroid 2
IGF1 (Homo sapiens)
GH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 2 96.20 Very High Very High Very High
tolerance 23 63.60 Quite High
Somatostatin 1 8.44 Low Low
corticosteroid 1 5.00 Very Low Very Low Very Low
carpal tunnel syndrome 1 5.00 Very Low Very Low Very Low
headache 1 5.00 Very Low Very Low Very Low
imagery 1 5.00 Very Low Very Low Very Low
cva 1 5.00 Very Low Very Low Very Low
Catecholamine 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Nutritional Deficiencies 5 99.04 Very High Very High Very High
INFLAMMATION 2 96.20 Very High Very High Very High
Thyroid Disease 2 93.48 High High
Insulin Resistance 16 87.40 High High
Obesity 54 75.92 Quite High
Impaired Glucose Tolerance 24 63.60 Quite High
Laron Syndrome 15 63.56 Quite High
Growth Problems 3 9.68 Low Low
Hypoglycemia 13 6.12 Low Low
Diabetes Mellitus 31 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thyroid and nutritional deficiencies should be corrected before initiating rhIGF-1. rhIGF-1 is not a substitute for GH17,19
rhIGF-1 Neg (not) Positive_regulation (substitute) of Gene_expression (17,19) of GH in Thyroid associated with nutritional deficiencies
1) Confidence 0.22 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724186 Disease Relevance 0.66 Pain Relevance 0.08
After nine months of GH treatment, serum IGF-1 in the GH group increased to 262.2 ± 35.1 ng/ml (an increase of 145.9 ± 33.3 ng/ml above baseline IGF-1) and to 256 ± 36.2 ng/ml in the GH + PIO group (an increase of 112.1 ± 34.8 ng/ml above baseline IGF-1).
IGF-1 Positive_regulation (increased) of Gene_expression (group) of GH
2) Confidence 0.10 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1865086 Disease Relevance 0.52 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox